Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).

Suzuki N, Hazama S, Nagasaka T, Tanioka H, Iwamoto Y, Negoro Y, Yamauchi M, Kobayashi M, Okuda H, Fujishima N, Nishimura T, Yamanaka N, Toyota K, Mori Y, Nakagami Y, Shimokawa M, Nagano H, Okajima M.

Int J Clin Oncol. 2019 Oct;24(10):1223-1230. doi: 10.1007/s10147-019-01473-3. Epub 2019 May 29.

2.

Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.

Hashimoto D, Arima K, Nakagawa S, Negoro Y, Hirata T, Hirota M, Inomata M, Fukuzawa K, Ohga T, Saeki H, Oki E, Yamashita YI, Chikamoto A, Baba H, Maehara Y.

J Gastroenterol. 2019 May;54(5):437-448. doi: 10.1007/s00535-018-01535-9. Epub 2018 Dec 4.

PMID:
30515563
3.

Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.

Negoro Y, Yano R, Yoshimura M, Suehiro Y, Yamashita S, Kodawara T, Watanabe K, Tsukamoto H, Nakamura T, Kadowaki M, Morikawa M, Umeda Y, Anzai M, Ishizuka T, Goto N.

Int J Clin Oncol. 2019 Mar;24(3):256-261. doi: 10.1007/s10147-018-1358-4. Epub 2018 Oct 17.

PMID:
30328531
4.

Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer.

Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y, Moran M, Astrow SH, Hsiang J, Stephens C, Fujii M, Ichikawa W.

Mol Cancer Ther. 2018 Dec;17(12):2788-2795. doi: 10.1158/1535-7163.MCT-18-0694. Epub 2018 Oct 1.

PMID:
30275242
5.

Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

Sunakawa Y, Yang D, Cao S, Zhang W, Moran M, Astrow SH, Hsiang J, Stephens C, Tsuji A, Takahashi T, Tanioka H, Negoro Y, Takagane A, Tani S, Yamaguchi T, Eto T, Fujii M, Ichikawa W, Lenz HJ.

Clin Colorectal Cancer. 2018 Dec;17(4):e741-e749. doi: 10.1016/j.clcc.2018.08.002. Epub 2018 Aug 23.

PMID:
30219280
6.

99mTc-GSA SPECT/CT fusion imaging for hepatectomy candidates with extremely deteriorated ICG value.

Sumiyoshi T, Okabayashi T, Negoro Y, Hata Y, Noda Y, Sui K, Iwata J, Matsumoto M.

Jpn J Radiol. 2018 Sep;36(9):537-543. doi: 10.1007/s11604-018-0753-0. Epub 2018 Jun 12.

PMID:
29948545
7.

Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma.

Sumiyoshi T, Shima Y, Okabayashi T, Negoro Y, Shimada Y, Iwata J, Matsumoto M, Hata Y, Noda Y, Sui K, Sueda T.

World J Surg. 2018 Sep;42(9):2910-2918. doi: 10.1007/s00268-018-4558-1.

PMID:
29511872
8.

First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.

Makiyama A, Kunieda K, Noguchi M, Kajiwara T, Tamura T, Takeda K, Sugiyama J, Minashi K, Moriwaki T, Sugimoto N, Nagase M, Negoro Y, Tsuda T, Shimodaira H, Okano N, Tsuji A, Sakai D, Yanagihara K, Ueda S, Tamura S, Otsu S, Honda T, Matsushita Y, Okuno T, Kashiwada T, Nozaki A, Ebi M, Okuda H, Shimokawa M, Hironaka S, Hyodo I, Baba E, Boku N, Muro K, Esaki T.

Gastric Cancer. 2018 Sep;21(5):792-801. doi: 10.1007/s10120-018-0797-y. Epub 2018 Jan 20.

PMID:
29353332
9.

CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.

Sunakawa Y, Tsuji A, Denda T, Segawa Y, Negoro Y, Shimada K, Kochi M, Nakamura M, Kotaka M, Tanioka H, Takagane A, Tani S, Yamaguchi T, Watanabe T, Takeuchi M, Fujii M, Ichikawa W.

Target Oncol. 2017 Dec;12(6):787-794. doi: 10.1007/s11523-017-0527-0.

PMID:
29064002
10.

A novel utility of 99mTc-GSA SPECT/CT fusion imaging: detection of inadequate portal vein embolization.

Sumiyoshi T, Shima Y, Okabayashi T, Hata Y, Noda Y, Kouno M, Saisaka Y, Sui K, Morita S, Negoro Y, Sueda T.

Jpn J Radiol. 2017 Dec;35(12):748-754. doi: 10.1007/s11604-017-0689-9. Epub 2017 Oct 16.

PMID:
29039109
11.

The Use of External-beam Radiotherapy for Muscle-invasive Bladder Cancer in Elderly or Medically-fragile Patients.

Aizawa R, Sakamoto M, Orito N, Kono M, Ogura M, Negoro Y, Sagoh T, Tsukahara K, Komatsu K, Noguchi M.

Anticancer Res. 2017 Oct;37(10):5761-5766.

PMID:
28982898
12.

Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).

Miura Y, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K, Moriwaki T, Negoro Y, Kimura Y, Uchino K, Shinozaki K, Shinozaki H, Musha N, Yoshiyama H, Tsuda T, Miyata Y, Sugimoto N, Shirakawa T, Ito M, Yonesaka K, Yoshimura K, Boku N, Nosho K, Takano T, Hyodo I.

Gastric Cancer. 2018 Jan;21(1):84-95. doi: 10.1007/s10120-017-0725-6. Epub 2017 May 11.

PMID:
28497176
13.

Anti-Müllerian hormone as a predictor of polycystic ovary syndrome treated with clomiphene citrate.

Hestiantoro A, Negoro YS, Afrita Y, Wiweko B, Sumapradja K, Natadisastra M.

Clin Exp Reprod Med. 2016 Dec;43(4):207-214. doi: 10.5653/cerm.2016.43.4.207. Epub 2016 Dec 26.

14.

[Molecular Targeted Therapy for Gastric Cancer].

Negoro Y, Shimada Y.

Gan To Kagaku Ryoho. 2016 Sep;43(9):1063-9. Japanese. No abstract available.

PMID:
27997087
15.

Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.

Sunakawa Y, Ichikawa W, Tsuji A, Denda T, Segawa Y, Negoro Y, Shimada K, Kochi M, Nakamura M, Kotaka M, Tanioka H, Takagane A, Tani S, Yamaguchi T, Watanabe T, Takeuchi M, Fujii M, Nakajima T.

Clin Colorectal Cancer. 2017 Sep;16(3):e171-e180. doi: 10.1016/j.clcc.2016.09.010. Epub 2016 Oct 6.

PMID:
27856123
16.

Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer.

Takaoka T, Kimura T, Shimoyama R, Kawamoto S, Sakamoto K, Goda F, Miyamoto H, Negoro Y, Tsuji A, Yoshizaki K, Goji T, Kitamura S, Yano H, Okamoto K, Kimura M, Okahisa T, Muguruma N, Niitsu Y, Takayama T.

Cancer Chemother Pharmacol. 2016 Aug;78(2):397-403. doi: 10.1007/s00280-016-3096-5. Epub 2016 Jun 24.

PMID:
27342247
17.

Epiploic gonadal vein as a new bypass route for extrahepatic portal venous obstruction: report of a case.

Sumiyoshi T, Shima Y, Okabayashi T, Negoro Y, Kozuki A, Iwata J, Saisaka Y, Tokumaru T, Nakamura T, Morita S.

Surg Case Rep. 2015 Dec;1(1):109. doi: 10.1186/s40792-015-0112-7. Epub 2015 Oct 23.

18.

Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).

Nishina T, Moriwaki T, Shimada M, Higashijima J, Sakai Y, Masuishi T, Ozeki M, Amagai K, Negoro Y, Indo S, Denda T, Sato M, Yamamoto Y, Nakajima G, Mizuta M, Takahashi I, Hiroshima Y, Ishida H, Maeba T, Hyodo I.

Clin Colorectal Cancer. 2016 Sep;15(3):236-42. doi: 10.1016/j.clcc.2015.12.001. Epub 2015 Dec 17.

PMID:
26778644
19.

The Inhibitory Effect of Ciprofloxacin on the β-Glucuronidase-mediated Deconjugation of the Irinotecan Metabolite SN-38-G.

Kodawara T, Higashi T, Negoro Y, Kamitani Y, Igarashi T, Watanabe K, Tsukamoto H, Yano R, Masada M, Iwasaki H, Nakamura T.

Basic Clin Pharmacol Toxicol. 2016 May;118(5):333-7. doi: 10.1111/bcpt.12511. Epub 2015 Dec 2.

20.

Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG).

Nishimura Y, Jingu K, Itasaka S, Negoro Y, Murakami Y, Karasawa K, Kawaguchi G, Isohashi F, Kobayashi M, Itoh Y, Ariga T.

Int J Clin Oncol. 2016 Feb;21(1):88-94. doi: 10.1007/s10147-015-0872-x. Epub 2015 Jul 16.

PMID:
26178368
21.

Variations in the Blood Phenytoin Levels during Long-Term Combined Treatment with S-1 and Phenytoin.

Negoro Y, Higashi T, Matsuoka H, Watanabe K, Igarashi T, Kayano Y, Yano R, Nakamura T, Masada M.

Case Rep Oncol. 2014 Sep 26;7(3):656-61. doi: 10.1159/000368077. eCollection 2014 Sep-Dec.

22.

Prevalence and outcomes of acute hepatitis B in Okayama, Japan, 2006-2010.

Wada N, Yasunaka T, Ikeda F, Nishina S, Korenaga M, Hino K, Fujioka S, Osawa T, Itoshima T, Kawanaka M, Yamada G, Kariyama K, Takayama H, Kubota J, Morimoto Y, Mizushima T, Yamashita H, Tanioka H, Negoro Y, Toshimori J, Kobashi H, Hirano A, Itano Y, Takaki A, Yamamoto K.

Acta Med Okayama. 2014;68(4):243-7.

23.

Comparison of the outcomes of stereotactic body radiotherapy and surgery in elderly patients with cT1-2N0M0 non-small cell lung cancer.

Nakagawa T, Negoro Y, Matsuoka T, Okumura N, Dodo Y.

Respir Investig. 2014 Jul;52(4):221-6. doi: 10.1016/j.resinv.2014.01.002. Epub 2014 Feb 26.

PMID:
24998368
24.

Efficacy of intraoperative radiotherapy targeted to the abdominal lymph node area in patients with esophageal carcinoma.

Tamaki Y, Sasaki R, Ejima Y, Ogura M, Negoro Y, Nakajima T, Murakami M, Kaji Y, Sugimura K.

J Radiat Res. 2012 Nov 1;53(6):882-91. doi: 10.1093/jrr/rrs045. Epub 2012 Aug 7.

25.

Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021).

Nishimura Y, Hiraoka M, Koike R, Nakamatsu K, Itasaka S, Kawamura M, Negoro Y, Araki N, Ishikawa H, Fujii T, Mitsuhashi N.

Jpn J Clin Oncol. 2012 Sep;42(9):807-12. doi: 10.1093/jjco/hys112. Epub 2012 Jul 17.

PMID:
22811410
26.

Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey.

Nishimura Y, Koike R, Ogawa K, Sasamoto R, Murakami Y, Itoh Y, Negoro Y, Itasaka S, Sakayauchi T, Tamamoto T.

Int J Clin Oncol. 2012 Feb;17(1):48-54. doi: 10.1007/s10147-011-0254-y. Epub 2011 May 25.

PMID:
21607829
27.

High-frequency Lamb wave device composed of MEMS structure using LiNbO3 thin film and air gap.

Kadota M, Ogami T, Yamamoto K, Tochishita H, Negoro Y.

IEEE Trans Ultrason Ferroelectr Freq Control. 2010 Nov;57(11):2564-71. doi: 10.1109/TUFFC.2010.1722.

PMID:
21041143
28.

Impact of double-balloon rectal catheter use in external-beam radiotherapy for prostate cancer.

Takayama K, Mizowaki T, Negoro Y, Norihisa Y, Hiraoka M.

Int J Clin Oncol. 2011 Feb;16(1):50-6. doi: 10.1007/s10147-010-0129-7. Epub 2010 Oct 5.

29.

Double-stranded DNA-templated cleavage of oligonucleotides containing a P3'->N5' linkage triggered by triplex formation: the effects of chemical modifications and remarkable enhancement in reactivity.

Ito KR, Kodama T, Tomizu M, Negoro Y, Orita A, Osaki T, Hosoki N, Tanaka T, Imanishi T, Obika S.

Nucleic Acids Res. 2010 Nov;38(20):7332-42. doi: 10.1093/nar/gkq600. Epub 2010 Jul 8.

30.

Intraoperative radiotherapy for resected pancreatic cancer: a multi-institutional retrospective analysis of 210 patients.

Ogawa K, Karasawa K, Ito Y, Ogawa Y, Jingu K, Onishi H, Aoki S, Wada H, Kokubo M, Etoh H, Kazumoto T, Takayama M, Negoro Y, Nemoto K, Nishimura Y; JROSG Working Subgroup of Gastrointestinal Cancers.

Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):734-42. doi: 10.1016/j.ijrobp.2009.09.010. Epub 2010 Mar 6.

PMID:
20207498
31.

A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021).

Nishimura Y, Mitsumori M, Hiraoka M, Koike R, Nakamatsu K, Kawamura M, Negoro Y, Fujiwara K, Sakurai H, Mitsuhashi N.

Radiother Oncol. 2009 Aug;92(2):260-5. doi: 10.1016/j.radonc.2008.12.012. Epub 2009 Jan 21.

PMID:
19167122
32.

Acid-mediated cleavage of oligonucleotide P3' --> N5' phosphoramidates triggered by sequence-specific triplex formation.

Obika S, Tomizu M, Negoro Y, Osaki T, Orita A, Ueyama Y, Nakagawa O, Imanishi T.

Nucleosides Nucleotides Nucleic Acids. 2007;26(8-9):893-6.

PMID:
18058503
33.

Patterns of care study of breast-conserving therapy in Japan: comparison of the treatment process between 1995 1997 and 1999 2001 surveys.

Yamauchi C, Mitsumori M, Sai H, Imagunbai T, Negoro Y, Sasaki Y, Hiraoka M, Shikama N, Sasaki S, Takegawa H, Inoue T, Teshima T.

Jpn J Clin Oncol. 2007 Oct;37(10):737-43. Epub 2007 Oct 2.

PMID:
17911378
34.

Double-stranded DNA-templated oligonucleotide digestion triggered by triplex formation.

Obika S, Tomizu M, Negoro Y, Orita A, Nakagawa O, Imanishi T.

Chembiochem. 2007 Nov 5;8(16):1924-8. No abstract available.

PMID:
17868159
35.

A case of mixed connective tissue disease presenting with nephrotic syndrome.

Kuroda H, Ishii K, Negoro Y, Sugiyama H, Inoue J, Ogurusu C, Kikuchi T, Shimoe K, Sunami K.

Mod Rheumatol. 2004;14(3):236-40.

PMID:
17143681
36.

Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.

Mitsumori M, Sasaki Y, Mizowaki T, Takayama K, Nagata Y, Hiraoka M, Negoro Y, Sasai K, Kinoshita H, Kamoto T, Ogawa O.

Int J Clin Oncol. 2006 Oct;11(5):396-402.

PMID:
17058138
37.

The patterns of care study for breast-conserving therapy in Japan: analysis of process survey from 1995 to 1997.

Mitsumori M, Hiraoka M, Negoro Y, Yamauchi C, Shikama N, Sasaki S, Yamamoto T, Teshima T, Inoue T.

Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1048-54.

PMID:
15990008
38.

Treatment planning of stereotactic radiotherapy for solitary lung tumor.

Takayama K, Nagata Y, Negoro Y, Mizowaki T, Sakamoto T, Sakamoto M, Aoki T, Yano S, Koga S, Hiraoka M.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1565-71.

PMID:
15817363
39.

18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy.

Ishimori T, Saga T, Nagata Y, Nakamoto Y, Higashi T, Mamede M, Mukai T, Negoro Y, Aoki T, Hiraoka M, Konishi J.

Ann Nucl Med. 2004 Dec;18(8):669-74.

PMID:
15682847
40.

Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance.

Aoki T, Nagata Y, Negoro Y, Takayama K, Mizowaki T, Kokubo M, Oya N, Mitsumori M, Hiraoka M.

Radiology. 2004 Jan;230(1):101-8. Epub 2003 Nov 26.

PMID:
14645881
41.

[Three-dimensional conformal radiotherapy for extracranial tumors using a stereotactic body frame]

Nagata Y, Negoro Y, Aoki T, Mizowaki T, Takayama K, Kokubo M, Araki N, Mitsumori M, Yano S, Koga Y, Hiraoka M.

Igaku Butsuri. 2001;21(1):28-34. Japanese.

PMID:
12766310
42.

Clinical evaluation of dynamic arc conformal radiotherapy for paraaortic lymph node metastasis.

Aoki T, Nagata Y, Mizowaki T, Kokubo M, Negoro Y, Takayama K, Mitsumori M, Sasai K, Hiraoka M.

Radiother Oncol. 2003 Apr;67(1):113-8.

PMID:
12758247
43.

Limy bile syndrome complicated with primary hyperparathyroidism.

Takatori Y, Yamauchi K, Negoro Y, Noro K, Yoshida A, Nanamiya W, Tamai M, Kobayashi T, Yamane Y, Akamoto S, Suzaki N, Sasaki A.

Intern Med. 2003 Jan;42(1):44-7.

44.

Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame.

Nagata Y, Negoro Y, Aoki T, Mizowaki T, Takayama K, Kokubo M, Araki N, Mitsumori M, Sasai K, Shibamoto Y, Koga S, Yano S, Hiraoka M.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1041-6.

PMID:
11958900
45.

Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure.

Oya N, Shibamoto Y, Nagata Y, Negoro Y, Hiraoka M.

J Neurooncol. 2002 Jan;56(1):87-94.

PMID:
11949831
46.

The effectiveness of an immobilization device in conformal radiotherapy for lung tumor: reduction of respiratory tumor movement and evaluation of the daily setup accuracy.

Negoro Y, Nagata Y, Aoki T, Mizowaki T, Araki N, Takayama K, Kokubo M, Yano S, Koga S, Sasai K, Shibamoto Y, Hiraoka M.

Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):889-98.

PMID:
11429216
47.

The use of a permanent magnetic resonance imaging system for radiotherapy treatment planning of bone metastases.

Mizowaki T, Araki N, Nagata Y, Negoro Y, Aoki T, Hiraoka M.

Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):605-11.

PMID:
11173161
48.

Reproducibility of geometric distortion in magnetic resonance imaging based on phantom studies.

Mizowaki T, Nagata Y, Okajima K, Kokubo M, Negoro Y, Araki N, Hiraoka M.

Radiother Oncol. 2000 Nov;57(2):237-42.

PMID:
11054528
49.

Transverse instability of solitary waves in the generalized kadomtsev-petviashvili equation

Kataoka T, Tsutahara M, Negoro Y.

Phys Rev Lett. 2000 Apr 3;84(14):3065-8.

PMID:
11019013
50.

Biochemical markers of bone turnover during hormone replacement therapy.

Masahashi T, Negoro Y, Kuroki T, Asai M, Noguchi M, Nakanishi M.

Int J Gynaecol Obstet. 1999 Feb;64(2):163-6.

PMID:
10189026

Supplemental Content

Loading ...
Support Center